NEW YORK (GenomeWeb) – Becton Dickinson said today that its BD Max MDR-TB panel has received CE-IVD status and is now available in Europe.

The PCR-based panel is intended to help detect tuberculosis-causing bacteria and determine if the bacteria contains mutations associated with resistance to isoniazid and rifampicin, two important first-line TB drugs.

The assay runs on the BD Max system, a fully integrated and automated molecular diagnostics platform that can run up to 24 samples across multiple tests and provides results for most assays in less than three hours.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Nov
15

This webinar will discuss how Amyris, a biotechnology company that develops renewable products for a broad range of applications and industries, uses large-scale microbial engineering to support its manufacturing processes.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec
12

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.